2019-11-14T16:26:37-06:00 2018-12-31 814234542 BPM LLP 10 ALMADEN BOULEVARD SUITE 1000 SAN JOSE CA 951132238 990 2018-01-01 204284925 QUANTUM LEAP HEALTHCARE COLLABORATIVE QUAN 8558660505 3450 CALIFORNIA STREET SAN FRANCISCO CA 941181837 DAVE MANDELKERN CHAIR 8558660505 2019-11-08 1 MICHAEL STEPHEN SCHAFFER P00210063 4089616300 2019-11-08 208.184.139.130 2019-11-08 12:36:43 PS P DA39A3EE5E6B4B0D3255BFEF95601890AFD80709 FD6251F6FB7123D4B026EB6814EBA84C6E349BAE 2018 2020-03-31 21:24:44Z JAMES PALAZZOLO 3450 CALIFORNIA STREET SAN FRANCISCO CA 941181837 12445452 0 X WWW.QUANTUMLEAPHEALTH.ORG X 2005 CA THE MISSION OF QUANTUM LEAP HEALTHCARE COLLABORATIVE IS TO PROVIDE MANAGEMENT AND FINANCIAL SUPPORT TO HEALTHCARE RESEARCH ORGANIZATIONS, PARTICULARLY INVOLVING BREAST CANCER RESEARCH AND TREATMENT. 9 8 17 8 0 1956 3033157 1203352 9456138 11242100 0 0 0 0 12489295 12445452 0 29000 0 0 1663809 2067461 118500 0 408525 8819449 9624111 10601758 11720572 1887537 724880 11141939 13623504 11349148 13096013 -207209 527491 X THE MISSION OF QUANTUM LEAP HEALTHCARE COLLABORATIVE IS TO PROVIDE MANAGEMENT AND FINANCIAL SUPPORT TO HEALTHCARE RESEARCH ORGANIZATIONS, PARTICULARLY INVOLVING BREAST CANCER RESEARCH AND TREATMENT. 0 0 9081918 11232100 I-SPY TRIALS: QUANTUM LEAP SPONSORS THE I-SPY TRIALS (INVESTIGATION OF SERIAL STUDIES TO PREDICT YOUR THERAPEUTIC RESPONSE WITH IMAGING AND MOLECULAR ANALYSIS). I-SPY HAS BEEN RE-ENGINEERING THE APPROACH TO CLINICAL TRIALS, WITH A GOAL OF GETTING THE RIGHT DRUG TO THE RIGHT PATIENT AT THE TIME WHEN THEY WILL BENEFIT MOST, AND TO ACHIEVE THIS FASTER THAN POSSIBLE IN PREVIOUS TRIAL MODELS. ADDITIONALLY, I-SPY AIMS TO SIGNIFICANTLY REDUCE THE OVERALL COST, TIME, AND NUMBER OF PATIENTS REQUIRED TO BRING NEW DRUGS TO MARKET. THE I-SPY TRIAL PROGRAM INTEGRATES AND LINKS PHASE I (I-SPY PHASE 1), PHASE II (I-SPY 2), AND FUTURE PHASES TO BUILD A PIPELINE OF NOVEL AGENTS AND ACCELERATE THE PROCESS OF IDENTIFYING THE SUBSET OF HIGH RISK BREAST CANCER PATIENTS THAT WILL BENEFIT FROM THESE NEW AGENTS, AND GET THESE DRUG INTO THE CLINIC IN A TIMELY MANNER. 548421 10000 BCTMATCH: BREASTCANCERTRIALS.ORG (BCT) IS A PATIENT-CENTERED WEBSITE DESIGNED TO INCREASE PUBLIC AWARENESS AND ACCESS TO CLINICAL TRIALS. LAUNCHED IN 2008, FOLLOWING A SUCCESSFUL UCSF-NCI SPONSORED RESEARCH PILOT, ITS MISSION IS TO MAKE PATIENT CONSIDERATION OF TRIALS THE NORM VERSUS THE EXCEPTION. THE GOAL OF BCT IS THAT ALL PATIENTS SHOULD HAVE ACCESS TO THE LATEST MEDICAL KNOWLEDGE ABOUT BREAST CANCER TREATMENT AS WELL AS THE OPPORTUNITY TO ADVANCE BREAST CANCER RESEARCH. 283522 COLLABORATION WITH THE ATHENA BREAST HEALTH NETWORK: THE ATHENA BREAST HEALTH NETWORK IS A COLLABORATION OF THE FIVE UNIVERSITY OF CALIFORNIA MEDICAL CENTERS AND SANFORD HEALTH TO DRIVE INNOVATION IN BREAST CANCER PREVENTION, SCREENING AND TREATMENT. A LARGE-SCALE DEMONSTRATION PROJECT, ATHENA INTEGRATES CLINICAL CARE AND RESEARCH TO DRIVE INNOVATION IN PREVENTION, SCREENING, TREATMENT AND MANAGEMENT OF BREAST CANCER.THIS PROJECT WILL IMPROVE SURVIVAL AND REDUCE SUFFERING FROM BREAST CANCER BY ACCELERATING THE TIME BETWEEN RESEARCH DISCOVERIES AND INNOVATIVE PATIENT TREATMENTS. MAJOR INITIATIVES INCLUDE RISK ASSESSMENT AND EVALUATION, RADIOLOGY HARMONIZATION, PATHOLOGY HARMONIZATION, AND IMPROVING SURVIVORSHIP CARE. ONE OF ATHENA'S CURRENT INITIATIVES IS THE WISDOM STUDY. THIS FIVE-YEAR STUDY WILL INVOLVE APPROXIMATELY 100,000 WOMEN 40 TO 80 YEARS OLD. IT WILL TEST A MORE TARGETED APPROACH TO BREAST CANCER SCREENING: THOSE AT HIGHER RISK ARE SCREENED MORE OFTEN AND THOSE AT LOWER RISK ARE SCREENED LESS OFTEN. ANNUAL SCREENING WILL BE WEIGHED AGAINST A PERSONALIZED SCHEDULE OF SCREENING BASED ON EACH WOMAN'S INDIVIDUAL RISK.QUANTUM LEAP PROVIDES IT AND SOFTWARE DEVELOPMENT SUPPORT, MARKETING SUPPORT, AND FUNDRAISING ASSISTANCE FOR THE ATHENA BREAST HEALTH NETWORK. 315573 29000 315573 29000 10229434 1 1 0 0 0 0 0 0 0 0 1 0 0 0 0 1 0 1 0 0 0 0 0 0 0 0 0 1 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 1 1 0 0 0 1 27 0 1 17 1 0 0 0 0 0 0 0 0 0 0 0 0 X 9 8 0 0 0 0 0 0 0 1 1 0 0 1 1 1 1 1 0 1 1 0 CA X X X THE ORGANIZATION 8558660505 3450 CALIFORNIA STREET SAN FRANCISCO CA 941181837 ROBERT PATTERSON CHAIR 0.50 X X 0 0 0 DAVE MANDELKERN CEO 24.00 X X 206876 0 0 ANNA BARKER DIRECTOR 0.50 X 0 0 0 LUCAS DEBREED DIRECTOR 0.50 X 0 0 0 LAURA ESSERMAN DIRECTOR 20.00 X 0 0 0 SUSAN FOLEY TREASURER 0.50 X X 0 0 0 JEFFREY PFEFFER DIRECTOR 0.50 X 0 0 0 ROBYN LAWRIE RUTLEDGE DIRECTOR 0.50 X 0 0 0 MARK SIMON DIRECTOR 0.50 X 0 0 0 ADAM ASARE CHIEF DATA OFFICER 40.00 X 218400 0 8736 SMITA ASARE DIRECTOR OF CLINICAL TRIALS 40.00 X 139400 0 33237 KARYN DIGIORGIO COO 40.00 X 204481 0 7479 NANCY LISSER DIRECTOR OF LEGAL AFFAIRS 40.00 X 149350 0 41612 MICHAEL RESENDEZ SENIOR SOFTWARE ENGINEER 40.00 X 143100 0 32240 1061607 0 123304 6 0 1 0 HEALTHCARE IT LEADERS 925 NORTH PINT PKWAY SUITE 425 ALPHARETTA GA 30005 QUALITY ASSURANCE/PROJECT MANAGEMENT 239325 DAVID MANDELKERN PO BOX 19564 STANFORD CA 94309 INTERIM CHIEF EXECUTIVE OFFICER 206876 SURESH GADAMSETTY 1501 DECOTO ROAD APT 118 UNION CITY CA 94587 BUSINESS DEVELOPMENT AND TECHNICAL ASSIS 151509 OPENCLINICA LLC 460 TOTTEN POND ROAD SUITE 200 WALTHAM MA 02451 CLINICAL DATA MANAGEMENT 124150 4 1203352 1203352 PROJECT MANAGEMENT REVENUE 541511 11232100 11232100 CONSULTING AND RESEARCH CONTRACTS 541511 10000 10000 11242100 12445452 11242100 0 0 29000 29000 224715 145639 53232 25844 1445002 936515 342300 166187 58321 38398 13420 6503 221617 132785 44687 44145 117806 73844 29769 14193 83551 33725 49826 79902 79902 1119502 710167 284665 124670 70958 14604 55822 532 160676 98704 42875 19097 261306 233306 21812 6188 12902 12902 50819 31710 19109 PROGRAM MANAGEMENT 4381118 4381118 RESEARCH SITES 3162327 3162327 PROGRAM EXPENSES 117349 117349 RESEARCH 43700 43700 80001 46543 32292 1166 11720572 10229434 1082613 408525 7158858 9999821 1040000 454000 2803472 3026845 52742 50498 33220 18160 19187 15060 67680 77280 11141939 13623504 9719148 10484013 1630000 2612000 11349148 13096013 X -3541952 -2086653 3334743 2614144 -207209 527491 11141939 13623504 724880 9600 220 0 X 0 1 X 1 0 X 266491 808721 1285937 3033157 1203352 6597658 266491 808721 1285937 3033157 1203352 6597658 3326148 3271510 299 199 498 6598156 41086021 0.49580 0.21770 X RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED 33220 18160 15060 15060 X PART X, LINE 2: QUANTUM LEAP IS EXEMPT FROM FEDERAL AND STATE INCOME TAXES UNDER THE PROVISIONS OF SECTION 501(C)(3) AND SECTION 170(B)(1)(A)(VI) OF THE INTERNAL REVENUE CODE AND CORRESPONDING PROVISIONS OF THE CALIFORNIA REVENUE AND TAXATION CODE. ACCORDINGLY, NO PROVISION FOR INCOME TAXES HAS BEEN MADE IN THE ACCOMPANYING FINANCIAL STATEMENTS. QUANTUM LEAP MAY BE SUBJECT TO UNRELATED BUSINESS INCOME TAX. 0 UNIVERSITY OF CHICAGO 6054 S DREXEL AVENUE CHICAGO IL 60637 362177139 501(C)(3) 29000 WISDOM STUDY 1 0 X 0 0 0 0 0 0 0 0 0 DAVE MANDELKERN CEO 206876 0 0 0 0 0 0 0 0 0 206876 0 0 0 ADAM ASARE CHIEF DATA OFFICER 218400 0 0 0 0 0 8736 0 0 0 227136 0 0 0 SMITA ASARE DIRECTOR OF CLINICAL TRIALS 139400 0 0 0 0 0 5576 0 27661 0 172637 0 0 0 KARYN DIGIORGIO COO 204481 0 0 0 0 0 7479 0 0 0 211960 0 0 0 NANCY LISSER DIRECTOR OF LEGAL AFFAIRS 149350 0 0 0 0 0 4481 0 37131 0 190962 0 0 0 MICHAEL RESENDEZ SENIOR SOFTWARE ENGINEER 143100 0 0 0 0 0 4293 0 27947 0 175340 0 0 0 FORM 990, PART VI, SECTION B, LINE 11B FORM 990 IS PREPARED BY AN INDEPENDENT CPA FIRM IN CONJUNCTION WITH THE ORGANIZATION'S DIRECTOR OF FINANCE. A DRAFT OF FORM 990 IS REVIEWED BY THE DIRECTOR OF FINANCE, AND CORRECTIONS/MODIFICATIONS ARE MADE BY THE OUTSIDE CPA. THE REVISED DRAFT IS THEN REVIEWED BY THE DIRECTOR OF FINANCE. ANY CONCERNS ARE RAISED WITH THE CPA FIRM AND A CONSENSUS IS ACHIEVED. BOARD MEMBERS ARE SENT A COPY OF THE TAX RETURN PRIOR TO FILING FOR THEIR REVIEW. THE RETURN IS THEN FINALIZED AND ELECTRONICALLY FILED WITH THE TAXING AUTHORITIES. FORM 990, PART VI, SECTION B, LINE 12C THE CONFLICT OF INTEREST POLICY IS PRESENTED AND REVIEWED ANNUALLY. EACH BOARD MEMBER IS REQUIRED TO ACKNOWLEDGE IN WRITING THAT NO CONFLICT EXISTS. FORM 990, PART VI, SECTION B, LINE 15 COMPENSATION OF THE PRESIDENT OF THE ORGANIZATION WAS DETERMINED AND APPROVED BY VOTE OF THE EXECUTIVE COMMITTEE OF THE BOARD OF DIRECTORS. PERSONNEL OF UCSF REVIEWED JOB REQUIREMENTS AGAINST TECHNICAL ABILITIES OF SUBCONTRACTORS AND DETERMINED WHETHER OR NOT THEY MATCHED. ALL SUBCONTRACTORS WERE ENGAGED AT BELOW-MARKET RATES. FORM 990, PART VI, SECTION C, LINE 19 ALL GOVERNING DOCUMENTS, AUDITED FINANCIAL STATEMENTS AND FORM 990, RETURN OF ORGANIZATION EXEMPT FROM INCOME TAX, ARE PROVIDED UPON WRITTEN REQUEST OR THROUGH THE QUANTUM LEAP HEALTHCARE COLLABORATIVE WEBSITE, AS WELL AS TO ANYONE WHO REQUESTS THEM IN WRITING. THEY ARE ALSO AVAILABLE FOR INSPECTION AT THE QLHC OFFICE DURING NORMAL BUSINESS HOURS. CENTER FOR CLINICAL INNOVATION DBA ENCOMPASS HEALTH FOUNDATION 320 FAIRWAY DRIVE HALF MOON BAY CA 94019 461637647 FUNDING CLINICAL RESEARCH AND INITIATIVES CA 501(C)(3) LINE 7 QUANTUMLEAP HEALTHCARE COLLABORATIVE 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 PART II THE CENTER FOR CLINICAL INNOVATION WAS DISSOLVED IN JUNE, 2019.